Hypertriglyceridemia as a Result of Human apo CII Gene Expression in Transgenic Mice
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Primary and secondary hypertriglyceridemia is common in the general population, but the biochemical basis for this disease is largely unknown. With the use of transgenic technology, two lines of mice were created that express the human apolipoprotein CIII gene. One of these mouse lines with 100 copies of the gene was found to express large amounts of the protein and to be severely hypertriglyceridemic. The other mouse line with one to two copies of the gene expressed low amounts of the protein, but nevertheless manifested mild hypertriglyceridemia. Thus, overexpression of apolipoprotein CIII can be a primary cause of hypertriglyceridemia in vivo and may provide one possible etiology for this common disorder in humans.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“High ApoC-III levels were shown to increase total triglyceride levels by an accumulation of VLDL and chylomicrons [166–169]”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [167]
In the citing paper
“These data are consistent with previous studies showing that transgenic mice with overexpression of human apolipoprotein C3 had hypertriglyceridemia due to decreased lipoprotein lipase activity,16”
From Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease (2010) · cites this paper as [16]
Citations
Cites
The Metabolic Basis of Inherited Disease.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-503_7 · Cited by 7,786
NF-κB: A pleiotropic mediator of inducible and tissue-specific gene control
Lenardo, M. J., & Baltimore, D. (1989) · Cell · doi:10.1016/0092-8674(89)90833-7 · Cited by 1,585
Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein
Virgil Brown, W., & Baginsky, M. L. (1972) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(72)80149-9 · Cited by 491
Ginsberg, H. N., Le, N. A., Goldberg, I. J., Gibson, J. C., Rubinstein, A., Wang-Iverson, P., Norum, R., & Brown, W. V. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112713 · Cited by 424
Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III.
Wang, C. S., McConathy, W. J., Kloer, H. U., & Alaupovic, P. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111711 · Cited by 414
Karathanasis, S. K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.19.6374 · Cited by 358
PLASMA TRIGLYCERIDE AS A RISK FACTOR FOR CORONARY HEART DISEASE
AUSTIN, M. A. (1989) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115130 · Cited by 352
Familial Deficiency of Apolipoproteins A-I and C-III and Precocious Coronary-Artery Disease
Norum, R. A., Lakier, J. B., Goldstein, S., Angel, A., Goldberg, R. B., Block, W. D., Noffze, D. K., Dolphin, P. J., Edelglass, J., Bogorad, D. D., et al. (1982) · New England Journal of Medicine · doi:10.1056/nejm198206243062503 · Cited by 304
Weintraub, M. S., Eisenberg, S., & Breslow, J. L. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112926 · Cited by 261
Self-citationWalsh, A., Ito, Y., & Breslow, J. L. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)83374-9 · Cited by 241
Self-citation
Research works printed but not linked: 2
- COLE, T.G., BIOCOMMUNIQUE 4: 4 (1988).
- PROTTER, A. A., DNA-A JOURNAL OF MOLECULAR & CELLULAR BIOLOGY 3: 449 (1984).
Cited by
Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism*
Desvergne, B., & Wahli, W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.5.0380 · Cited by 3,086
Role of LXRs in control of lipogenesis
Schultz, J. R., Tu, H., Luk, A., Repa, J. J., Medina, J. C., Li, L., Schwendner, S., Wang, S., Thoolen, M., Mangelsdorf, D. J., et al. (2000) · Genes & Development · doi:10.1101/gad.850400 · Cited by 1,499
Schoonjans, K., Staels, B., & Auwerx, J. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42003-6 · Cited by 1,216
Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state
Patsch, J. R., Miesenböck, G., Hopferwieser, T., Mühlberger, V, Knapp, E., Dunn, J. K., Gotto, A. M., & Patsch, W. (1992) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.12.11.1336 · Cited by 1,122
Schoonjans, K., Staels, B., & Auwerx, J. (1996) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(96)00066-5 · Cited by 1,047
Sladek, F. M., Zhong, W. M., Lai, E., & Darnell, J. E. (1990) · Genes & Development · doi:10.1101/gad.4.12b.2353 · Cited by 1,027
An Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing
Pennacchio, L. A., Olivier, M., Hubacek, J. A., Cohen, J. C., Cox, D. R., Fruchart, J.-C., Krauss, R. M., & Rubin, E. M. (2001) · Science · doi:10.1126/science.1064852 · Cited by 921
Zhong, S., Sharp, D. S., Grove, J. S., Bruce, C., Yano, K., Curb, J. D., & Tall, A. R. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118751 · Cited by 583
The role of FoxO in the regulation of metabolism
Gross, D. N., van den Heuvel, A. P. J., & Birnbaum, M. J. (2008) · Oncogene · doi:10.1038/onc.2008.25 · Cited by 540
Role of apoCs in lipoprotein metabolism: functional differences between apoC1, apoC2, and apoC3
Jong, M. C., Hofker, M. H., & Havekes, L. M. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.3.472 · Cited by 539
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528
Animal models of nonalcoholic fatty liver disease
Hebbard, L., & George, J. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.191 · Cited by 499
Targeting APOC3 in the familial chylomicronemia syndrome
Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400284 · Cited by 491
Aalto-Setälä, K., Fisher, E. A., Chen, X., Chajek-Shaul, T., Hayek, T., Zechner, R., Walsh, A., Ramakrishnan, R., Ginsberg, H. N., & Breslow, J. L. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116066 · Cited by 450
Self-citationMorton, N. M., Holmes, M. C., Fiévet, C., Staels, B., Tailleux, A., Mullins, J. J., & Seckl, J. R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103676200 · Cited by 439
Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease
Petersen, K. F., Dufour, S., Hariri, A., Nelson-Williams, C., Foo, J. N., Zhang, X.-M., Dziura, J., Lifton, R. P., & Shulman, G. I. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907295 · Cited by 428
Staels, B., Vu-Dac, N., Kosykh, V. A., Saladin, R., Fruchart, J. C., Dallongeville, J., & Auwerx, J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117717 · Cited by 410
Mode of Action of Peroxisome Proliferators as Hypolipidemic Drugs.
Hertz, R., Bishara-Shieban, J., & Bar-Tana, J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.13470 · Cited by 339
Maeda, N., Li, H., Lee, D., Oliver, P., Quarfordt, S. H., & Osada, J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31559-4 · Cited by 313
Foxo1 mediates insulin action on apoC-III and triglyceride metabolism
Altomonte, J., Lin, C., Harbaran, S., Richter, A. M., Xu, J., Meseck, M. L., & Dong, H. H. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19992 · Cited by 309
Agellon, L. B., Walsh, A., Hayek, T., Moulin, P., Jiang, X. C., Shelanski, S. A., Breslow, J. L., & Tall, A. R. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99088-5 · Cited by 298
Self-citationApolipoproteins C-I and C-III as important modulators of lipoprotein metabolism
Shachter, N. S. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200106000-00009 · Cited by 288
Apolipoprotein C-III: understanding an emerging cardiovascular risk factor
Ooi, E. M. M., Barrett, P. H. R., Chan, D. C., & Watts, G. F. (2008) · Clinical Science · doi:10.1042/cs20070308 · Cited by 282
Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression
Claudel, T., Inoue, Y., Barbier, O., Duran-Sandoval, D., Kosykh, V., Fruchart, J., Fruchart, J.-C., Gonzalez, F. J., & Staels, B. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00896-5 · Cited by 268
Mietus-Snyder, M., Sladek, F. M., Ginsburg, G. S., Kuo, C. F., Ladias, J. A., Darnell, J. E., & Karathanasis, S. K. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.4.1708 · Cited by 281
Li, W. W., Dammerman, M. M., Smith, J. D., Metzger, S., Breslow, J. L., & Leff, T. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118324 · Cited by 278
Self-citationApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors
Gordts, P. L. S. M., Nock, R., Son, N.-H., Ramms, B., Lew, I., Gonzales, J. C., Thacker, B. E., Basu, D., Lee, R. G., Mullick, A. E., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86610 · Cited by 274
Hayek, T., Masucci-Magoulas, L., Jiang, X., Walsh, A., Rubin, E., Breslow, J. L., & Tall, A. R. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118255 · Cited by 265
Self-citationGenetic determinants of plasma triglycerides
Johansen, C. T., Kathiresan, S., & Hegele, R. A. (2011) · Journal of Lipid Research · doi:10.1194/jlr.r009720 · Cited by 263
PLASMA LIPID TRANSFER PROTEINS, HIGH-DENSITY LIPOPROTEINS, AND REVERSE CHOLESTEROL TRANSPORT
Bruce, C., Chouinard, R. A., & Tall, A. R. (1998) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.18.1.297 · Cited by 258
Selective Hepatic Insulin Resistance, VLDL Overproduction, and Hypertriglyceridemia
Sparks, J. D., Sparks, C. E., & Adeli, K. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.241463 · Cited by 231
Qiao, J. H., Xie, P. Z., Fishbein, M. C., Kreuzer, J., Drake, T. A., Demer, L. L., & Lusis, A. J. (1994) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.14.9.1480 · Cited by 240
Dammerman, M., Sandkuijl, L. A., Halaas, J. L., Chung, W., & Breslow, J. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.10.4562 · Cited by 227
Self-citationZheng, C., Khoo, C., Furtado, J., & Sacks, F. M. (2010) · Circulation · doi:10.1161/circulationaha.109.875807 · Cited by 223
Lipoprotein Genotype and Conserved Pathway for Exceptional Longevity in Humans
Atzmon, G., Rincon, M., Schechter, C. B., Shuldiner, A. R., Lipton, R. B., Bergman, A., & Barzilai, N. (2006) · PLoS Biology · doi:10.1371/journal.pbio.0040113 · Cited by 222
de Silva, H. V., Lauer, S. J., Wang, J., Simonet, W. S., Weisgraber, K. H., Mahley, R. W., & Taylor, J. M. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42171-5 · Cited by 208
Simonet, W. S., Bucay, N., Lauer, S. J., & Taylor, J. M. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53085-4 · Cited by 215
Del Bas, J. M., Fernández-Larrea, J., Blay, M., Ardèvol, A., Salvadó, M. J., Arola, L., & Bladé, C. (2005) · The FASEB Journal · doi:10.1096/fj.04-3095fje · Cited by 205
Overexpression and Accumulation of Apolipoprotein E as a Cause of Hypertriglyceridemia
Huang, Y., Liu, X. Q., Rall, S. C., Taylor, J. M., von Eckardstein, A., Assmann, G., & Mahley, R. W. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.41.26388 · Cited by 204
Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5
Fruchart-Najib, J., Baugé, E., Niculescu, L.-S., Pham, T., Thomas, B., Rommens, C., Majd, Z., Brewer, B., Pennacchio, L. A., & Fruchart, J.-C. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.05.003 · Cited by 198
The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
Borén, J., Packard, C. J., & Taskinen, M.-R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00474 · Cited by 196
“Earlier studies have reported that PPARα agonists reduce APOC3 and plasma apoC-III levels (30, 33, 127).”
BackgroundEbara, T., Ramakrishnan, R., Steiner, G., & Shachter, N. S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119456 · Cited by 191
Chen, M., Breslow, J. L., Li, W., & Leff, T. (1994) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39938-7 · Cited by 184
Self-citationApolipoprotein C-III: from pathophysiology to pharmacology
Norata, G. D., Tsimikas, S., Pirillo, A., & Catapano, A. L. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.07.001 · Cited by 182
“As example, in patients with HTG and T2DM, apoC-III-enriched LDL exhibited an altered lipid composition compared with apoC-III-free LDL, increased binding to proteoglycans and lipoprotein retention, and increased LDL susceptibility to hydrolysis and aggregation by sphingomyelinase (Figure 3) [32,66,67].”
BackgroundInfluentialLarsson, M., Vorrsjö, E., Talmud, P., Lookene, A., & Olivecrona, G. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.495366 · Cited by 169
Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III.
McConathy, W., Gesquiere, J., Bass, H., Tartar, A., Fruchart, J. C., & Wang, C. (1992) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41415-4 · Cited by 173
A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia
Kao, J.-T. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg255 · Cited by 170
Venkatesan, S., Cullen, P., Pacy, P., Halliday, D., & Scott, J. (1993) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.13.7.1110 · Cited by 175
Cohn, J. S., Patterson, B. W., Uffelman, K. D., Davignon, J., & Steiner, G. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032056 · Cited by 170
Pennacchio, L. A., & Rubin, E. M. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000054194.78240.45 · Cited by 168
Caron, S., Verrijken, A., Mertens, I., Samanez, C. H., Mautino, G., Haas, J. T., Duran-Sandoval, D., Prawitt, J., Francque, S., Vallez, E., et al. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.220723 · Cited by 162
KATOH, N. (2002) · Journal of Veterinary Medical Science · doi:10.1292/jvms.64.293 · Cited by 161
LIPOPROTEINS AND ATHEROGENESIS
Hoeg, J. M. (1998) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70026-8 · Cited by 167
The apoAI-CIII-AIV gene cluster
Groenendijk, M. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(01)00539-1 · Cited by 164
Brewer, H. B. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00308-2 · Cited by 173
Shen, B., Zhao, C., Wang, Y., Peng, Y., Cheng, J., Li, Z., Wu, L., Jin, M., & Feng, H. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14293 · Cited by 163
Auwerx, J., Schoonjans, K., Fruchart, J.-C., & Staels, B. (1996) · Atherosclerosis · doi:10.1016/0021-9150(96)05854-6 · Cited by 158
Willems van Dijk, K., Rensen, P. C., Voshol, P. J., & Havekes, L. M. (2004) · Current Opinion in Lipidology · doi:10.1097/00041433-200406000-00002 · Cited by 154
Merkel, M., Kako, Y., Radner, H., Cho, I. S., Ramasamy, R., Brunzell, J. D., Goldberg, I. J., & Breslow, J. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13841 · Cited by 150
Self-citationAddressing dyslipidemic risk beyond LDL-cholesterol
Tall, A. R., Thomas, D. G., Gonzalez-Cabodevilla, A. G., & Goldberg, I. J. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148559 · Cited by 150
Streeper, R. S., Svitek, C. A., Chapman, S., Greenbaum, L. E., Taub, R., & O'Brien, R. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.18.11698 · Cited by 147
Lipoprotein Lipase: Recent Contributions from Molecular Biology
Auwerx, J., Leroy, P., & Schoonjans, K. (1992) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408369209114602 · Cited by 148
Vu-Dac, N., Gervois, P., Torra, I. P., Fruchart, J. C., Kosykh, V, Kooistra, T., Princen, H. M., Dallongeville, J., & Staels, B. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1581 · Cited by 143
“demia, whereas elimination of the endogenous apo C-III gene results in lowered plasma apo C-III concentrations and protects the animals against postprandial hypertriglyceridemia (13, 14).”
BackgroundOverexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice.
Shachter, N. S., Hayek, T., Leff, T., Smith, J. D., Rosenberg, D. W., Walsh, A., Ramakrishnan, R., Goldberg, I. J., Ginsberg, H. N., & Breslow, J. L. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117151 · Cited by 139
Self-citationA Mouse Model with Features of Familial Combined Hyperlipidemia
Masucci-Magoulas, L., Goldberg, I. J., Bisgaier, C. L., Serajuddin, H., Francone, O. L., Breslow, J. L., & Tall, A. R. (1997) · Science · doi:10.1126/science.275.5298.391 · Cited by 142
Self-citationBerbée, J. F. P., van der Hoogt, C. C., Sundararaman, D., Havekes, L. M., & Rensen, P. C. N. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m400301-jlr200 · Cited by 137
Raspé, E., Duez, H., Gervois, P., Fiévet, C., Fruchart, J.-C., Besnard, S., Mariani, J., Tedgui, A., & Staels, B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m004982200 · Cited by 134
PPARγ activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes
Martin, G., Schoonjans, K., Staels, B., & Auwerx, J. H. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(97)00315-8 · Cited by 160
The APOA1/C3/A4/A5 gene cluster, lipid metabolism and cardiovascular disease risk
Lai, C.-Q., Parnell, L. D., & Ordovas, J. M. (2005) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000162320.54795.68 · Cited by 137
Jong, M. C., Rensen, P. C. N., Dahlmans, V. E. H., van der Boom, H., van Berkel, T. J. C., & Havekes, L. M. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32211-2 · Cited by 136
Apolipoprotein A-V-heparin Interactions
Lookene, A., Beckstead, J. A., Nilsson, S., Olivecrona, G., & Ryan, R. O. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501589200 · Cited by 130
Effects of HIV protease inhibitor therapy on lipid metabolism
Hui, D. Y. (2003) · Progress in Lipid Research · doi:10.1016/s0163-7827(02)00046-2 · Cited by 155
Lee, H.-Y., Birkenfeld, A. L., Jornayvaz, F. R., Jurczak, M. J., Kanda, S., Popov, V., Frederick, D. W., Zhang, D., Guigni, B., Bharadwaj, K. G., et al. (2011) · Hepatology · doi:10.1002/hep.24571 · Cited by 134
Hayek, T., Azrolan, N., Verdery, R. B., Walsh, A., Chajek-Shaul, T., Agellon, L. B., Tall, A. R., & Breslow, J. L. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116683 · Cited by 133
Self-citationUpdate on the molecular biology of dyslipidemias
Ramasamy, I. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.10.033 · Cited by 155
GENETICS OF LIPOPROTEIN ABNORMALITIES ASSOCIATED WITH CORONARY HEART DISEASE SUSCEPTIBILITY
Breslow, J. L. (2000) · Annual Review of Genetics · doi:10.1146/annurev.genet.34.1.233 · Cited by 129
Self-citationStructure and functional properties of lipoprotein lipase
Wang, C., Hartsuck, J. A., & McConathy, W. J. (1992) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(92)90165-r · Cited by 128
Hui, T. Y., Sheth, S. S., Diffley, J. M., Potter, D. W., Lusis, A. J., Attie, A. D., & Davis, R. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401280200 · Cited by 127
Raspé, E., Madsen, L., Lefebvre, A.-M., Leitersdorf, I., Gelman, L., Peinado-Onsurbe, J., Dallongeville, J., Fruchart, J.-C., Berge, R., & Staels, B. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32433-0 · Cited by 128
Shimada, M., Shimano, H., Gotoda, T., Yamamoto, K., Kawamura, M., Inaba, T., Yazaki, Y., & Yamada, N. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)46793-7 · Cited by 125
Murray, I., Havel, P. J., Sniderman, A. D., & Cianflone, K. (2000) · Endocrinology · doi:10.1210/endo.141.3.7364 · Cited by 109
Russo, G. T., Meigs, J. B., Cupples, L. A., Demissie, S., Otvos, J. D., Wilson, P. W. F., Lahoz, C., Cucinotta, D., Couture, P., Mallory, T., et al. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(01)00409-9 · Cited by 143
Transgenic mouse models of lipoprotein metabolism and atherosclerosis.
Breslow, J. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8314 · Cited by 123
Self-citationImpaired chylomicron remnant clearance in familial combined hyperlipidemia.
Cabezas, M. C., de Bruin, T. W., Jansen, H., Kock, L. A., Kortlandt, W., & Erkelens, D. W. (1993) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.13.6.804 · Cited by 125
Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl.
Shachter, N. S., Ebara, T., Ramakrishnan, R., Steiner, G., Breslow, J. L., Ginsberg, H. N., & Smith, J. D. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118857 · Cited by 117
Self-citationThe Mystery of Diabetes and Atherosclerosis: Time for a New Plot
Semenkovich, C. F., & Heinecke, J. W. (1997) · Diabetes · doi:10.2337/diab.46.3.327 · Cited by 136
Haubenwallner, S., Essenburg, A. D., Barnett, B. C., Pape, M. E., DeMattos, R. B., Krause, B. R., Minton, L. L., Auerbach, B. J., Newton, R. S., & Leff, T. (1995) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41090-9 · Cited by 119
GPIHBP1, an endothelial cell transporter for lipoprotein lipase
Young, S. G., Davies, B. S. J., Voss, C. V., Gin, P., Weinstein, M. M., Tontonoz, P., Reue, K., Bensadoun, A., Fong, L. G., & Beigneux, A. P. (2011) · Journal of Lipid Research · doi:10.1194/jlr.r018689 · Cited by 108
Gene-diet interaction in determining plasma lipid response to dietary intervention
Ordovás, J. M., López‐Miranda, J., Mata, P., Pérez‐Jiménez, F., Lichtenstein, A. H., & Schaefer, E. J. (1995) · Atherosclerosis · doi:10.1016/0021-9150(95)90069-1 · Cited by 126
Fredenrich, A., Giroux, L. M., Tremblay, M., Krimbou, L., Davignon, J., & Cohn, J. S. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37424-1 · Cited by 114
Aalto-Setälä, K., Weinstock, P. H., Bisgaier, C. L., Wu, L., Smith, J. D., & Breslow, J. L. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39123-9 · Cited by 114
Self-citationPlasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects.
Batal, R., Tremblay, M., Barrett, P. H. R., Jacques, H., Fredenrich, A., Mamer, O., Davignon, J., & Cohn, J. S. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32379-8 · Cited by 113
Coleman, T., Seip, R. L., Gimble, J. M., Lee, D., Maeda, N., & Semenkovich, C. F. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.21.12518 · Cited by 113
Auwerx, J. H., Schoonjans, K., Fruchart, J., & Staels, B. (1996) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat1994.3.81 · Cited by 120
Polymorphic Markers in Apolipoprotein C-III Gene Flanking Regions and Hypertriglyceridemia
Surguchov, A. P., Page, G. P., Smith, L., Patsch, W., & Boerwinkle, E. (1996) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.16.8.941 · Cited by 108
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109
Nowak, M., Helleboid-Chapman, A., Jakel, H., Martin, G., Duran-Sandoval, D., Staels, B., Rubin, E. M., Pennacchio, L. A., Taskinen, M.-R., Fruchart-Najib, J., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.4.1537-1548.2005 · Cited by 107
The Role of Lipids and Lipoproteins in Atherosclerosis
Linton, M. F., Yancey, P. G., Davies, S. S., Jerome, W. G., Linton, E. F., Song, W., Doran, A. C., & Vickers, K. C. (2015) · Europe PMC (PubMed Central) · Cited by 153
Dallinga‐Thie, G. M., Bu, X. D., Trip, M. V. L.-S., Rotter, J. I., Lusis, A. J., & de Bruin, T. W. A. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37642-2 · Cited by 120
Apolipoprotein C-III in triglyceride-rich lipoprotein metabolism
Ramms, B., & Gordts, P. L. S. M. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000502 · Cited by 101
Metadata
- Authors
- Ito, Y., Azrolan, N., O'Connell, A., Walsh, A., & Breslow, J. L.
- Affiliations
- Rockefeller University (US)
- Venue
- Science
- Published
- 1990-08-17
- Volume
- 249
- Issue
- 4970
- Pages
- 790-793
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1963872182
- Semantic Scholar
- be3dbcf0ed6239b54ab96520181db05f1ba0399f
- Cited by
- 539
- References
- 32
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 7 · 2023: 9 · 2022: 7 · 2021: 10 · 2020: 9 · 2019: 16 · 2018: 10 · 2017: 17 · 2016: 13 · 2015: 15 · 2014: 16 · 2013: 18 · 2012: 7
- FWCI
- 21.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01hl033714-17, 5r37hl036461-09)
- National Heart, Lung, and Blood Institute (HL 33714, HL-36461, HL-33435)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Keywords
- hypertriglyceridemia, apolipoprotein C-III, transgenic mice, gene overexpression, primary hypertriglyceridemia, secondary hypertriglyceridemia, triglyceride metabolism, gene dosage
- MeSH terms
- Animals, Apolipoproteins C, Chylomicrons, Cloning, Molecular, DNA Restriction Enzymes, DNA, Recombinant, Humans, Lipoproteins, VLDL, Mice, Inbred CBA, Mice, Inbred C57BL, Mice, Transgenic, Nucleic Acid Hybridization, RNA, Messenger, Triglycerides, Hypertriglyceridemia, Gene Expression, Mice, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.